| 1.46 0.08 (5.8%) | 12-15 15:25 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.94 | 1-year : | 2.27 |
| Resists | First : | 1.66 | Second : | 1.94 |
| Pivot price | 1.3  |
|||
| Supports | First : | 1.17 | Second : | 0.87 |
| MAs | MA(5) : | 1.28 |
MA(20) : | 1.34  |
| MA(100) : | 1.58 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 69.6 |
D(3) : | 57.2 |
| RSI | RSI(14): 53.4 |
|||
| 52-week | High : | 2.75 | Low : | 0.87 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ ANL ] has closed below upper band by 30.4%. Bollinger Bands are 152.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 1.41 - 1.41 | 1.41 - 1.41 |
| Low: | 1.3 - 1.3 | 1.3 - 1.31 |
| Close: | 1.38 - 1.39 | 1.39 - 1.4 |
Adlai Nortye Ltd., a clinical-stage biotechnology company, engages in the research and development of pharmaceutical products. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trials for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trials to induce and stabilize PD-L1 dimerization and disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.
Wed, 03 Dec 2025
Adlai Nortye (NASDAQ:ANL) Shares Down 1.4% - Here's Why - MarketBeat
Wed, 03 Dec 2025
Adlai Nortye Ltd. Shareholders Approve Redomiciliation to Singapore - TipRanks
Fri, 21 Nov 2025
Adlai Nortye (NASDAQ: ANL) to present at Evercore and Oppenheimer healthcare conferences - Stock Titan
Wed, 22 Oct 2025
Adlai Nortye to Present Short Talk on AN4035 Preclinical - GlobeNewswire
Thu, 08 Aug 2024
Adlai Nortye Reports Unaudited First Half 2024 Financial Results and Highlights Recent Operational Progress - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 31 (M) |
| Held by Insiders | 6.671e+007 (%) |
| Held by Institutions | 8.5 (%) |
| Shares Short | 1 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -5.192e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 220.8 % |
| Return on Equity (ttm) | -32.9 % |
| Qtrly Rev. Growth | 1.94e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -52 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.06 |
| Dividend | 0 |
| Forward Dividend | 8520 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|